271. Ankylosing spondylitis Clinical trials / Disease details

Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00420238 (ClinicalTrials.gov)	January 2007	8/1/2007	Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis	A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: Etanercept (Enbrel);Other: Placebo	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	70 Years	All	82	Phase 4	France;Germany;Hungary;Netherlands
2	NCT01289743 (ClinicalTrials.gov)	February 2002	1/2/2011	Etanercept (Enbrel) in Ankylosing Spondylitis	An Open-label Study of Etanercept (Enbrel) Efficacy in Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: Etanercept	Charite University, Berlin, Germany	Rheumazentrum Ruhrgebiet	Active, not recruiting	18 Years	65 Years	Both	24	Phase 2	Germany